Strong Growth Potential for Oruka Therapeutics Driven by Robust Financials and Promising Drug Pipeline
LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on ORKA stock, giving a Buy rating today. Sam Slutsky’s rating ...
ETF Daily News6d
Analysts Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) Price Target at $43.17
Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) have earned a consensus rating of “Buy” from the eight ...
BioPharma Dive15d
Jade, another biotech spinout of Paragon, to merge with Aerovate
The immune disease drug developer expects to raise $300 million in a private financing set to close before its combination ...
Oruka Therapeutics files to sell 8.72M shares of common stock for holders
EST Oruka Therapeutics (ORKA) files to sell 8.72M shares of common stock for holders Published first on TheFly – the ultimate ...
Contrasting Oruka Therapeutics (ORKA) & The Competition
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 public companies in the “Diagnostic substances” industry, but how does it weigh in compared to its peers? We will compare Oruka ...
Yahoo Finance12d
Oruka Therapeutics to Present at Multiple November Investor Conferences
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin ...
Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical inflection points ORKA-001 non-human primate (NHP) pharmacokinetic and in vitro ...